LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Legal & Regulatory and Reimbursement/FDA Clears ‘First’ Oblique Anterior Lumbar Interbody Implant
Legal & Regulatory and Reimbursement

FDA Clears ‘First’ Oblique Anterior Lumbar Interbody Implant

April 11, 2022 2 min read Premium comments

Advertisement

#fda510kclearanceSecondary#asturamedical#elcapitan

On April 4, 2022, Texas-based Astura Medical announced the FDA 510(k) Clearance for its El Capitan Oblique Anterior Lumbar Interbody Fusion (ALIF) System. It is the company’s fourth clearance.

According to FDA documents, the system is indicated for intervertebral body fusion procedures in skeletally mature patients with degenerative disc disease of the lumbar spine at one or two contiguous levels from L1-L2 to L5-S1. These patients may also have up to Grade I spondylolisthesis or retrolisthesis at the involved levels.

The system, says the company, builds on the company’s other plate and spacer technologies addressing anterior cervical, lateral lumbar, and traditional anterior lumbar approaches. The company stated the lumbar system was specifically designed “to deliver the widest array of construct options with the most efficient and streamlined supporting instrumentation in the oblique anterior lumbar surgery marketplace today.”

“We set out to provide a system that would establish a higher benchmark for intraoperative versatility, flexibility, and efficiency in oblique anterior lumbar surgery,” said Tom Purcell, co-founder and vice president.

El Capitan

The company claims the El Capitan is the “first system to provide multiple, customizable plating and fixation options in oblique anterior lumbar procedures.” The plating options allow for either a Zero-Profile, Half Plate, or Full Plate that can be implanted in combination with the interbody from either a left or right sided approach. “By providing either Anchoring Nails or Screws, which can be delivered via multiple techniques including an All-in-One option, El Capitan Oblique can accommodate the wide variance of anatomical challenges presented in oblique anterior lumbar surgery.”

According to the FDA documents, the implants were developed for the substitution of the classical autogenous bone graft blocks.

The cages “assist to avoid complications” related to the bone graft donation site (chronic pain, hematoma, infection, bone removal from the donor site making it impossible to remove bone again, quality of the iliac bone, accessing a healthy donor site that may become an unhealthy site, hernias by the incision).

Advertisement

“The Spacers are a 2-piece modular design which allows for interchangeable plate and spacer components.

The plate and spacer components contain interlocking features in addition to a spring-loaded latch mechanism which allows for intraoperative assembly prior to implantation.”

The implants have a hollow center to allow placement of autogenous bone graft. The superior and inferior surfaces are open “to promote contact of the bone graft with the vertebral end plates, allowing bone growth (arthrodesis).”

Hyperlordotic interbody devices (>20° lordosis) and the Oblique interbody devices must, according to the FDA, be used with supplemental fixation (e.g., posterior fixation) that has been cleared by the FDA for use in the lumbar spine

Astura Medical

Astura Medical was formed in 2014. In 2019 the company relocated its corporate headquarters from Carlsbad, California to a new 40,000 square foot facility in Irving, Texas.

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy